JP2024532886A5 - - Google Patents
Info
- Publication number
- JP2024532886A5 JP2024532886A5 JP2024512952A JP2024512952A JP2024532886A5 JP 2024532886 A5 JP2024532886 A5 JP 2024532886A5 JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024512952 A JP2024512952 A JP 2024512952A JP 2024532886 A5 JP2024532886 A5 JP 2024532886A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- seq
- cancer
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/114549 | 2021-08-25 | ||
| CN2021114549 | 2021-08-25 | ||
| PCT/CN2022/114642 WO2023025215A1 (en) | 2021-08-25 | 2022-08-25 | ANTIBODIES AND VARIANTS THEREOF AGAINST HUMAN CD16a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024532886A JP2024532886A (ja) | 2024-09-10 |
| JP2024532886A5 true JP2024532886A5 (enExample) | 2025-09-01 |
Family
ID=85321557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024512952A Pending JP2024532886A (ja) | 2021-08-25 | 2022-08-25 | ヒトＣＤ１６ａに対する抗体及びその変異体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240352128A1 (enExample) |
| EP (1) | EP4392453A4 (enExample) |
| JP (1) | JP2024532886A (enExample) |
| KR (1) | KR20240049331A (enExample) |
| CN (1) | CN117858902A (enExample) |
| WO (1) | WO2023025215A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4676965A1 (en) * | 2023-03-03 | 2026-01-14 | Beone Medicines I GmbH | Cd16a antibodies and methods of use |
| EP4676975A1 (en) * | 2023-03-03 | 2026-01-14 | Beone Medicines I GmbH | Muc1 and cd16a antibodies and methods of use |
| WO2024206126A1 (en) * | 2023-03-27 | 2024-10-03 | Modernatx, Inc. | Cd16-binding antibodies and uses thereof |
| CN120025439B (zh) * | 2023-11-21 | 2026-04-17 | 南京融捷康生物科技有限公司 | 一种抗CD16a的单域抗体及其用途 |
| CN118221818B (zh) * | 2024-04-29 | 2025-01-24 | 四川大学 | 一种抗cd16a的纳米抗体及其应用 |
| CN121758624A (zh) * | 2024-09-23 | 2026-03-31 | 北京智仁美博生物科技有限公司 | 结合人cd16和/或人cd123的多种抗体及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2487932A1 (en) * | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| GB0510790D0 (en) * | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| CA2614766A1 (en) * | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods of treating autoimmune disease using humanized anti-cd16a antibodies |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| WO2018039626A1 (en) * | 2016-08-25 | 2018-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human single domain antibodies targeting cd16a to mediate adcc |
| AU2018226526B2 (en) * | 2017-02-28 | 2025-03-13 | Affimed Gmbh | Combination of an anti-CD16A antibody with a cytokine |
| US20240101677A1 (en) * | 2021-01-27 | 2024-03-28 | Innovent Biologics (Suzhou) Co., Ltd. | Single-domain antibody against cd16a and use thereof |
-
2022
- 2022-08-25 US US18/682,827 patent/US20240352128A1/en active Pending
- 2022-08-25 CN CN202280057501.6A patent/CN117858902A/zh active Pending
- 2022-08-25 JP JP2024512952A patent/JP2024532886A/ja active Pending
- 2022-08-25 WO PCT/CN2022/114642 patent/WO2023025215A1/en not_active Ceased
- 2022-08-25 KR KR1020247009137A patent/KR20240049331A/ko active Pending
- 2022-08-25 EP EP22860561.4A patent/EP4392453A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519254A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2021524249A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| US12269877B2 (en) | Anti-notch3 antibodies | |
| JP2022533418A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2023543493A5 (enExample) | ||
| CN102905723A (zh) | 抗fgfr2抗体 | |
| JP2021533796A5 (enExample) | ||
| JP2021520201A5 (enExample) | ||
| JP2022512642A5 (enExample) | ||
| JP2023518153A5 (enExample) | ||
| JP2022532991A5 (enExample) | ||
| JP2023510429A5 (enExample) | ||
| JP2023517794A5 (enExample) | ||
| JP2023545521A5 (enExample) | ||
| JP2024535930A5 (enExample) | ||
| JP2023533793A5 (enExample) | ||
| JP2023517754A5 (enExample) | ||
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| JP2023525991A5 (enExample) | ||
| AU2020266253A1 (en) | Combination of HER2 antibodies | |
| JP2024540062A5 (enExample) | ||
| US20220265821A1 (en) | Composition and methods of targeting the pre-b cell receptor for the treatment of leukemias and lymphomas |